Insmed Incorporated
Could not find a ticker for this position, may be a filing error
A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.
1.75% Convertible Senior Notes due 2025, redeemed August 9, 2024
Sold 1.55M
Granted 1.44M · Bought 165.0K
Granted 303.1K · Bought 334.6K · Sold 132.0K
Granted 2.89M · Bought 112.7K · Sold 1.93M
Granted 549.6K · Bought 43.3K
Granted 629.5K · Bought 80.0K
Granted 253.7K · Bought 258.8K
Granted 499.6K · Bought 74.8K
Granted 106.3K · Bought 10.0K
Granted 168.4K · Bought 10.0K
Granted 104.0K · Sold 6.3K
Granted 168.4K
Granted 168.4K
Granted 342.4K · Bought 30.0K · Sold 218.9K
Granted 151.2K · Sold 73.2K
Granted 421.3K · Bought 3.0K · Sold 320.5K
Granted 70.3K · Bought 3.0K
Granted 111.5K · Sold 42.0K
Granted 205.7K · Bought 10.0K
Granted 675.3K · Sold 610.2K
Granted 149.5K · Bought 19.0K · Sold 106.3K
Granted 66.6K
Granted 906.8K · Sold 839.3K
Granted 77.0K · Sold 15.0K
Granted 939.6K · Sold 878.1K
Granted 78.0K · Bought 45.0K · Sold 75.0K
Granted 174.6K · Sold 138.5K
Granted 45.0K
Granted 366.4K · Sold 354.0K
Granted 55.8K · Bought 2.0K
Granted 32.0K · Sold 6.5K
Granted 24.6K
Granted 16.0K
Granted 80.0K · Sold 65.0K
Granted 30.3K · Sold 25.0K
Granted 10.7K
Bought 10.0K
Granted 7.3K
Granted 18.8K · Sold 18.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| FMR LLCReporting owner · 42 transactions | — | 4.11Mas of Jul 2013 | — | — | 1.55M |
| Allan GeoffreyPresident, CEO and Chairman, Director · 6 transactions | — | 1.83Mas of Mar 2009 | 1.44M | 165.0K | — |
| Sharoky Melvin MDDirector · 115 transactions | — | 1.39M | 303.1K | 334.6K | 132.0K |
| Lewis WilliamChair and CEO, Director · 332 transactions | — | 1.14M | 2.89M | 112.7K | 1.93M |
| Tully Kevin PExecutive VP & CFO · 8 transactions | — | 377.3Kas of Mar 2009 | 549.6K | 43.3K | — |
| Glover Steve CPresident Follow-on Biologics · 10 transactions | — | 368.8Kas of Mar 2009 | 629.5K | 80.0K | — |
| Engelsen Steinar JDirector · 26 transactions | — | 320.8Kas of Nov 2021 | 253.7K | 258.8K | — |
| Farrar DougVice President, ITP · 9 transactions | — | 292.1Kas of Mar 2009 | 499.6K | 74.8K | — |
| Brennan David RDirector · 17 transactions | — | 251.2K | 106.3K | 10.0K | — |
| Crooke Graham KDirector · 4 transactions | — | 228.4Kas of Jun 2010 | 168.4K | 10.0K | — |
| McGirr David W JDirector · 17 transactions | — | 195.4K | 104.0K | — | 6.3K |
| Condon Kenneth GDirector · 3 transactions | — | 168.5Kas of Jun 2010 | 168.4K | — | — |
| Lanfear Dennis MDirector · 3 transactions | — | 168.4Kas of Jun 2010 | 168.4K | — | — |
| Pellizzari Christine AChief Legal Officer · 54 transactions | — | 150.0Kas of May 2021 | 342.4K | 30.0K | 218.9K |
| Wise John DraytonChief Commercial Officer · 30 transactions | — | 133.0Kas of Feb 2025 | 151.2K | — | 73.2K |
| Adsett RogerChief Operating Officer · 67 transactions | — | 98.6K | 421.3K | 3.0K | 320.5K |
| Desjardins ClarissaDirector · 10 transactions | — | 73.3K | 70.3K | 3.0K | — |
| Altomari AlfredDirector · 18 transactions | — | 69.5Kas of May 2024 | 111.5K | — | 42.0K |
| Whitcomb Randall WDirector · 12 transactions | — | 69.2Kas of Mar 2015 | 205.7K | 10.0K | — |
| Bonstein SaraChief Financial Officer · 78 transactions | — | 69.1K | 675.3K | — | 610.2K |
| Hayden Donald J JrDirector · 27 transactions | — | 68.5Kas of Apr 2019 | 149.5K | 19.0K | 106.3K |
| Schafer CarolDirector · 8 transactions | — | 66.6K | 66.6K | — | — |
| Schaeffer Orlov S NicoleChief People Strategy Officer · 110 transactions | — | 63.9K | 906.8K | — | 839.3K |
| Anderson Elizabeth MDirector · 11 transactions | — | 62.0K | 77.0K | — | 15.0K |
| Flammer Martina M.D.Chief Medical Officer · 133 transactions | — | 60.5K | 939.6K | — | 878.1K |
| Lee LeoDirector · 15 transactions | — | 58.0K | 78.0K | 45.0K | 75.0K |
| Soriano JohnChief Compliance Officer · 21 transactions | — | 52.6Kas of Sep 2021 | 174.6K | — | 138.5K |
| Drucker Andrea HoltzmanSVP, Gen. Counsel & Corp Sec. · 1 transaction | — | 45.0Kas of Jun 2013 | 45.0K | — | — |
| Smith Michael AlexanderChief Legal Officer · 84 transactions | — | 37.6K | 366.4K | — | 354.0K |
| Gupta RenuExecutive Vice President & CMO · 6 transactions | — | 37.0Kas of Jan 2014 | 55.8K | 2.0K | — |
| Potter Myrtle SDirector · 7 transactions | — | 25.5Kas of May 2018 | 32.0K | — | 6.5K |
| Kollender Richard SDirector · 4 transactions | — | 24.6Kas of Oct 2013 | 24.6K | — | — |
| Streck PaulChief Medical Officer · 2 transactions | — | 16.0Kas of Aug 2018 | 16.0K | — | — |
| Drechsler Andrew TChief Financial Officer · 8 transactions | — | 15.0Kas of Mar 2017 | 80.0K | — | 65.0K |
| Goll JohnChief Accounting Officer · 4 transactions | — | 14.4Kas of Jan 2020 | 30.3K | — | 25.0K |
| Tombesi PaoloChief Financial Officer · 1 transaction | — | 10.7Kas of Jan 2018 | 10.7K | — | — |
| Whitten TimothyPresident & CEO, Director · 2 transactions | — | 10.0Kas of Jun 2012 | — | 10.0K | — |
| Butera SamueleSVP, GM, Global Respiratory · 1 transaction | — | 7.3K | 7.3K | — | — |
| Quigley MarkVice President, Quality · 4 transactions | — | 0as of May 2015 | 18.8K | — | 18.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.19M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.